Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information (Details)

v3.25.1
Segment Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Segment Information    
Number of reportable segments | segment 1  
Revenue - related party $ 41 $ 103
Operating expenses:    
Operating expenses $ 56,215 $ 52,251
Segment Reporting, Other Segment Item, Composition, Description Other Segment Items include interest income, foreign currency exchange loss, and gain (loss) on common stock warrant liabilities. Other Segment Items include interest income, foreign currency exchange loss, and gain (loss) on common stock warrant liabilities.
Net Loss $ (56,240) $ (51,847)
Immunotherapy and targeted oncology therapy    
Segment Information    
Revenue - related party 41 103
Operating expenses:    
Employee Expenses 8,624 7,285
Stock-based compensation expense 15,252 2,897
Fortress Founder's Agreement and MSA Expenses 9,133 4,871
Manufacturing and Development Expenses 10,755 19,013
Clinical Expenses 3,901 6,981
Regulatory Expenses 334 3,615
License Fees 152 2,300
Legal & Accounting Expense 4,123 1,814
R&D Other Expense 1,629 1,439
G&A Other Expense 2,312 2,036
Operating expenses 56,215 52,251
Other Segment Items (66) 301
Net Loss $ (56,240) $ (51,847)